Protective immunity against heterologous challenge with encephalomyocarditis virus by VP1 DNA vaccination: effect of coinjection with a granulocyte-macrophage colony stimulating factor gene
Protective immunity against heterologous challenge with encephalomyocarditis virus by VP1 DNA vaccination: effect of coinjection with a granulocyte-macrophage colony stimulating factor gene
复制标题
DOI：
10.1016/s0264-410x(97)88856-1
复制
发表时间：
1997-12-01
期刊：
影响因子：
5.5
通讯作者：
Sung, YC
中科院分区：
文献类型：
--
作者：
Sin, JI;Sung, JH;Sung, YC
为了进行DNA疫苗的研究，从大肠杆菌中获得了重组的脑心肌炎病毒（EMCV）VP 1蛋白，构建了VP 1真核表达载体pCT-Gs-VP 1，并将其作为DNA疫苗。用重组VP 1免疫小鼠，在有或没有表达粒细胞-巨噬细胞集落刺激因子（GM-CSF）的质粒DNA存在下，用pCT-Gs-VP 1免疫小鼠，然后用ELISA法检测其抗VP 1的免疫应答。将pCT-Gs-VP 1和GM-CSF质粒DNA共注射小鼠，可提高单次DNA注射免疫小鼠的血清转化率，增强VP 1特异性免疫，对致死性病毒攻击的保护率达80%左右。因此，我们的研究结果为CM-CSF在DNA疫苗接种中诱导更好的免疫应答和抵抗病毒感染提供了证据。(C)1997 Elsevier Science Ltd.
For DNA vaccination studies, recombinant VP1 protein of encephalomyocarditis virus (EMCV) was produced from Escherichia coli, and eukaryotic VP1 expression vector pCT-Gs-VP1, was generated and used as a DNA vaccine, Mice were immunized intramuscularly (i.m.) with pCT-Gs-VP1 in the presence or absence of plasmid DNA expressing granulocyte-macrophage colony stimulating factor (GM-CSF), and were subsequently analyzed for their anti-VP1 immune responses with recombinant VPI in ELISA, Immunization of mice with pCT-Gs-VP1 resulted in I ipl-specific immune response and 43% protection from subsequent lethal heterologous challenge of EMCV. Coinjection of mice with pCT-Gs-VP1 and plasmid DNA encoding GM-CSF was shown to increase the seroconversion rate of the immunized mice with a single DNA injection, and enhanced to a higher degree VP1-specific immunity, which appeared to result in better protection (about 80%) from lethal virus challenge. Thus, our results provide evidence for the potential use of CM-CSF to induce better immune response and resistance against viral infection in DNA vaccination. (C) 1997 Elsevier Science Ltd.